Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS...

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pulmonary Medicine

Background:

• Acute respiratory distress syndrome (ARDS) is a critical condition with limited pharmacological treatments.
• Alveolar type 2 (AT2) epithelial cell dysfunction, including reduced proliferation and mechanical capacity in inflammatory settings, drives ARDS-related respiratory failure.

Purpose of the Study:

• To develop a precise therapeutic strategy for ARDS.
• To address the impaired proliferation and inflammatory environment affecting AT2 cells in ARDS.

Main Methods:

• Development of a biomimetic, self-adaptive nanoparticle: hollow mesoporous cerium oxide loaded with 7,8-dihydroxyflavone and coated with a platelet membrane (HCeO_x-D@PM).
• Utilizing the HCeO_x core for reactive oxygen species (ROS) scavenging and drug delivery.
• Employing the platelet membrane (PM) for targeted lung delivery and adaptive drug release.

Main Results:

• HCeO_x-D@PM effectively scavenges ROS, reducing inflammation and protecting AT2 cells.
• The nanoparticle facilitates targeted delivery and adaptive release of 7,8-dihydroxyflavone in response to specific protease activation.
• Demonstrated significant improvement in AT2 cell proliferation and enhanced survival rates in vivo.

Conclusions:

• HCeO_x-D@PM represents a promising advancement for precise ARDS treatment.
• The biomimetic nanoparticle effectively targets lung injury, modulates the inflammatory environment, and promotes cellular repair.
• This approach offers a potential new therapeutic avenue for lethal respiratory diseases like ARDS.